Why Salesforce is staying in the portfolio despite a harsh analyst downgrade

Salesforce shares slipped over 2% to around $162.50 after KeyBanc downgraded the stock to a hold-equivalent and removed its $290 price target. The note cites weak/unclear signals around a possible recovery and skepticism that Salesforce’s Agentforce AI platform is ready or compelling, while Benioff pushed back arguing Agentforce is improving (Agentforce ARR cited at $1.2B vs $800M prior quarter). The article also highlights broader “SaaSpocalypse” concerns about AI enabling customers to build/replace software in-house, leaving investors cautious despite an AI product push.

Analysis

The market is no longer pricing Salesforce as a “cheap AI beneficiary”; it’s treating CRM as a proof-of-concept risk. That matters because the stock’s next leg will be driven less by headline ARR claims and more by whether the company can convert pilot activity into visible billings, RPO, and seat retention. If the evidence stays anecdotal, the multiple can keep compressing even if reported revenue merely slows rather than collapses.

Competitive spillover is more important than the downgrade itself. If enterprises decide to build narrower internal agents for high-frequency workflows, the main damage falls on application-layer vendors like CRM, while budget migrates toward platform owners and integration shops: MSFT, IBM, and hyperscaler ecosystems can capture the work of stitching data, identity, and governance together. That said, messy enterprise data is also a moat; the risk is not immediate replacement, but pricing pressure and lower expansion rates as customers buy fewer incremental seats and more modular AI add-ons.

The key catalyst window is the next earnings cycle: any lack of clarity around Agentforce monetization, cRPO, or net retention will keep the “show me” trade in place for 1-3 months. The contrarian view is that the selloff may already reflect a worst-case “SaaSpocalypse” narrative, so a durable bottom likely requires either a broad software multiple reset or one clean quarter of improving enterprise spend data. A thesis break would be a clear step-up in AI attach rates and management giving auditable proof that Agentforce is driving incremental paid usage rather than marketing theater.

Key Decisions for Investors

• Tactically fade strength in CRM over the next 1-3 weeks; use a small short or bearish call spread, with the thesis invalidated if the company shows clear improvement in cRPO/NRR or discloses meaningful Agentforce monetization on the next call.
• Pair trade: long MSFT / short CRM for 1-3 months to express that enterprise AI budget is shifting toward platform distribution and embedded copilots rather than standalone seat-based app vendors. Cover the short if CRM demonstrates auditable attach-rate acceleration.
• Watch IBM as a second-order beneficiary of AI integration spend; it is not an immediate long, but if clients choose services-heavy modernization over vendor replacement, IBM can pick up budget that would otherwise have gone to CRM. Only act if consulting backlog and software mix improve.
• Avoid chasing a deep short in CRM here; the stock already screens as a crowded negative sentiment name. Better entry is into a post-rally bounce or ahead of earnings, with a hard stop if management produces measurable traction in paid AI usage.
• Use IGV as the broad software proxy if you want to isolate the sector read-through: short CRM vs long IGV only works if the market continues to reward platform names over application vendors; the trade fails if software multiples reflate indiscriminately.